Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers

Area of Science:

• Vascular Medicine
• Pharmacology

Background:

• Raynaud's phenomenon causes pain, disability, and digital infarction, often linked to vasospasm and vascular disease.
• Calcium-channel blockers are investigated for their vasodilatory effects and potential to improve peripheral blood flow.

Purpose of the Study:

• To evaluate the efficacy of calcium-channel blockers in treating Raynaud's phenomenon.
• To assess both subjective and objective measures of treatment response.

Main Methods:

• Prospective, randomized, double-blind, placebo-controlled trials were conducted.
• Diltiazem and nifedipine were tested, with verapamil at low doses also assessed.
• Patient groups included those with and without underlying vascular disease, including scleroderma.

Main Results:

• Diltiazem and nifedipine provided subjective improvement in 60-90% of patients.
• Low-dose verapamil was ineffective.
• Objective digital blood flow did not improve significantly.
• Patients without underlying vascular disease responded better than those with scleroderma.
• Adverse effects were infrequent and rarely required treatment cessation.

Conclusions:

• Nifedipine and diltiazem offer effective short-term symptomatic relief for most Raynaud's phenomenon patients.
• The benefits appear more pronounced in patients without significant underlying vascular disease.